Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

MINIMAL SAPONIN-BASED ADJUVANT VACCINE PLATFORM

Project description

Optimised adjuvants for potent vaccines

Vaccines utilise adjuvants to enhance and boost the immune response to the vaccine’s antigens. Adjuvants can stimulate the immune system and enhance antigen presentation, thereby promoting a stronger and more prolonged immune response. The ERC-funded ADJU-PLATFORM project aims to produce a potent yet safe saponin adjuvant using a previously developed synthetic platform. Compared to traditional adjuvants, ADJU-PLATFORM solutions offer high purity, modular design and cost efficiency, leading to improved vaccines. Researchers plan to optimise intellectual property strategies and build a commercialisation roadmap for accelerated market entry of vaccine solutions across multiple disease areas.

Objective

ADJU-PLATFORM seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the efficient production of optimised saponin adjuvants and improved cost-effective vaccines. We have recently developed in the laboratory a potent, safe, stable and streamlined platform based on an optimised version of the vaccine adjuvant QS-21 that has led to patent applications and raised the interest of the pharmaceutical industry. In this PoC project, we aim to exploit our synthetic saponin technology to produce scalable adjuvant and vaccine candidates that outperform existing products more cost-effectively, lowering the risk profile of the commercialisation potential, while also achieving valorisation outcomes for market entry. The goal is to demonstrate our innovative minimal adjuvant platform in relevant settings for the advancement of novel adjuvant prototypes and molecular vaccines closer to the market.

The breakthrough innovation potential of ADJU-PLATFORM lies in the exploitation of this adjuvant vaccine platform for its application with additional formulation systems in a range of disease areas, expanding and improving the available vaccine solutions. The high purity and excellent chemical control over our synthetic platform compared to the heterogeneous natural product adjuvants, as well as its streamlined, modular nature and low-cost profile are distinctive attributes of our technology that will be valorised herein, making it a potentially superior alternative to existing vaccine models with less structural definition and costlier timelines. The main objectives are (1) demonstrate our synthetic technology platform for the streamlined and efficient development of scalable adjuvant and vaccine solutions and (2) implement valorisation opportunities of our platform and products by establishing an optimal IPR strategy and a go-to-market roadmap for the commercialisation.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-POC1

See all projects funded under this call

Host institution

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE
Net EU contribution
€ 150 000,00
Address
PARQUE TECNOLOGICO EDIFICIO 801 A
48160 DERIO VIZCAYA
Spain
Region
Noreste País Vasco Bizkaia
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)